Search research articles
Contact Us
Filters
Showing results (61-70 of 96) with videos related to
Page
of 10
Sort By:
Gynecologic Oncology
|
August 15, 2022
Optimal timing of interval debulking surgery for advanced epithelial ovarian cancer: A retrospective study from the ESME national cohort
Quentin Dominique Thomas, Amal Boussere, Jean-Marc Classe, et al.
Frontiers in Pharmacology
|
October 7, 2021
Real-World Experience of Bevacizumab as First-Line Treatment for Ovarian Cancer: The GINECO ENCOURAGE Cohort of 468 French Patients
Dominique Berton, Anne Floquet, Willy Lescaut, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 30, 2009
A universal formula based on cystatin C to perform individual dosing of carboplatin in normal weight, underweight, and obese patients
Antonin Schmitt, Laurence Gladieff, Amélie Lansiaux, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
January 13, 2018
Genome profiling is an efficient tool to avoid the STUMP classification of uterine smooth muscle lesions: a comprehensive array-genomic hybridization analysis of 77 tumors
Sabrina Croce, Agnès Ducoulombier, Agnès Ribeiro, et al.
Gynecologic Oncology
|
December 25, 2021
Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial
Philipp Harter, Marie Ange Mouret-Reynier, Sandro Pignata, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 9, 2022
Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial
Paul DiSilvestro, Susana Banerjee, Nicoletta Colombo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 5, 2020
Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial
Paul DiSilvestro, Nicoletta Colombo, Giovanni Scambia, et al.
Gynecologic Oncology
|
February 6, 2022
A phase II study of Navitoclax (ABT-263) as single agent in women heavily pretreated for recurrent epithelial ovarian cancer: The MONAVI - GINECO study
Florence Joly, Michel Fabbro, Philippe Follana, et al.
Frontiers in Plant Science
|
December 7, 2017
The Challenge of Improving Soil Fertility in Yam Cropping Systems of West Africa
Emmanuel Frossard, Beatrice A Aighewi, Sévérin Aké, et al.
Ebiomedicine
|
October 23, 2020
Genetic markers and phosphoprotein forms of beta-catenin pβ-Cat552 and pβ-Cat675 are prognostic biomarkers of cervical cancer
Suzy M Scholl, Jonas Beal, Leanne de Koning, et al.
Page
of 10
Search research articles
Search
Showing results (61-70 of 96) with videos related to
Sort By:
Page
of 10
Gynecologic Oncology
|
August 15, 2022
Optimal timing of interval debulking surgery for advanced epithelial ovarian cancer: A retrospective study from the ESME national cohort
Quentin Dominique Thomas, Amal Boussere, Jean-Marc Classe, et al.
Frontiers in Pharmacology
|
October 7, 2021
Real-World Experience of Bevacizumab as First-Line Treatment for Ovarian Cancer: The GINECO ENCOURAGE Cohort of 468 French Patients
Dominique Berton, Anne Floquet, Willy Lescaut, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 30, 2009
A universal formula based on cystatin C to perform individual dosing of carboplatin in normal weight, underweight, and obese patients
Antonin Schmitt, Laurence Gladieff, Amélie Lansiaux, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
January 13, 2018
Genome profiling is an efficient tool to avoid the STUMP classification of uterine smooth muscle lesions: a comprehensive array-genomic hybridization analysis of 77 tumors
Sabrina Croce, Agnès Ducoulombier, Agnès Ribeiro, et al.
Gynecologic Oncology
|
December 25, 2021
Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial
Philipp Harter, Marie Ange Mouret-Reynier, Sandro Pignata, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 9, 2022
Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial
Paul DiSilvestro, Susana Banerjee, Nicoletta Colombo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 5, 2020
Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial
Paul DiSilvestro, Nicoletta Colombo, Giovanni Scambia, et al.
Gynecologic Oncology
|
February 6, 2022
A phase II study of Navitoclax (ABT-263) as single agent in women heavily pretreated for recurrent epithelial ovarian cancer: The MONAVI - GINECO study
Florence Joly, Michel Fabbro, Philippe Follana, et al.
Frontiers in Plant Science
|
December 7, 2017
The Challenge of Improving Soil Fertility in Yam Cropping Systems of West Africa
Emmanuel Frossard, Beatrice A Aighewi, Sévérin Aké, et al.
Ebiomedicine
|
October 23, 2020
Genetic markers and phosphoprotein forms of beta-catenin pβ-Cat552 and pβ-Cat675 are prognostic biomarkers of cervical cancer
Suzy M Scholl, Jonas Beal, Leanne de Koning, et al.
Page
of 10